Decreasing trend of blood lipid profile in type 2 diabetes: Not a promising change in HDL-C, a serial cross-sectional study

Abstract

Background The prevalence of dyslipidemia in patients with type 2 diabetes (T2D) has been reported to be relatively high. The current study aimed to investigate the trend of serum lipid levels and the prevalence of dyslipidemia in patients with T2D. Methods Data were extracted from a cohort of patients with T2D who had regular follow-ups every year for three years. TG, TC, LDL-C, HDL-C, and non-HDL-C were analyzed. The atherogenic index of plasma (AIP) was calculated using log (TG/HDL-C). Results A total of 747 patients with T2D were included in this study, consisting of 469 (62.8%) women and 278 (37.2%) men. There was a significant downward trend in mean TG, TC, LDL-C, non-HDL-C, and AIP levels. The trend of mean HDL-C levels showed no significant change. The prevalence of high TG, high TC, high LDL-C, and high non-HDL-C significantly decreased from the first to the last visit. There was no significant change in the trend of prevalence of low HDL-C. The prevalence of high AIP significantly decreased in women and showed no significant changes in men. Conclusions A decreasing trend was observed in the mean levels and prevalence of TG, TC, LDL-C, non-HDL-C, and AIP. HDL-C did not change significantly. The success rate in achieving a complete normal lipid profile during follow-up years was not promising and continues to be challenging.

ApoA1/HDL-C ratio as a predictor for coronary artery disease in patients with type 2 diabetes: a matched case-control study

“…Diabetes is an independent risk factor for CVD [ 7 ]. CVD risk factors such as dyslipidemia, hypertension, obesity, and autonomic dysfunction are also more prevalent in patients with diabetes [ 8 , 9 ]. Timely diagnosis of CVD in patients with diabetes faces challenges due to altered or obscured typical CVD symptoms [ 10 ].…”

Increased high-density lipoprotein cholesterol in patients with type 2 diabetes and its correlates: a cross-sectional, matched case–control survey

“…Atherosclerosis development could be protected through different HDL-C capacities, including cholesterol removal from the artery wall, vasodilation in endothelial cells, protective effects on low-density lipoprotein (LDL) oxidation, and anti-inflammatory effects[ 9 , 18 ]. To date, there is a lack of documented conclusive evidence for the effectiveness of HDL-C-raising drugs [ 9 , 19 , 20 ]. Although it has been shown that niacin and cholesterol ester transfer protein (CETP) inhibitors could lead to an increase in HDL-C levels, the cardiovascular risk was not substantially reduced using such medications [ 5 ].…”